Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 21;10(5):1356–1364.e2. doi: 10.1016/j.jaip.2021.12.038

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Spontaneous IFN-γ production by PBMCs from patients, as measured in an ELISpot assay. (A) Graphic representation of the ELISpot assays. cMCADs, patients with cMCADs; non-cMCAD control groups: MCAS, patients with idiopathic mast cell activation syndrome; CTR: non-cMCAD/non-MCAS control patients convalescing from COVID-19 (n = 32); HD, healthy donors. Empty circles: no history of COVID-19. Filled circles: history of COVID-19. Pictures of ELISpot assays. (B) A well with nonstimulated PBMCs from a COVID-19 non-cMCAD control. (C) A well with nonstimulated PBMCs from a patient with COVID-19 and cMCAD. (D) A well with PBMCs from a COVID-19 non-cMCAD control after stimulation for 18 to 20 hours with individual 15-mer 11-aa overlapping peptide pools derived from the SARS-CoV-2 N-terminal fragment spike protein. (E) A well with PBMCs from a patient with COVID-19 and cMCAD after stimulation with individual 15-mer 11-aa overlapping peptide pools derived from the SARS-CoV-2 N-terminal fragment spike protein.